pSubstantial morbidity and mortality remains associated with thrombotic events has stimulated the rapid expansion of the available armamentarium to combat pathologic thrombosis. Pathologic thrombosis plays an essential role in the pathogenesis of acute coronary syndromes ACS, ischemic complications of percutaneous coronary intervention PCI, venous thromboembolic disease, and embolic complications of arrhythmias and various cardiomyopathies.p pWritten by experts in the field, emAntithrombotic Drug Therapy in Cardiovascular Diseaseem carefully examines individual and various combinations of the available antithrombotic regimens including fibrinolytic agents, antiplatelet therapies aspirin, thieneopyridines, glycoprotein IIbIIIa inhibitors, and anticoagulant therapies unfractionated heparin, low-molecular-weight heparins, direct thrombin inhibitors, and synthetic factor X inhibitors, non-ST-segment elevation NSTE ACS and ST-segment elevation myocardial infarction STEMI. A detailed overvie